文献速递糖尿病

理解2型糖尿病患者使用GLP-1受体激动剂和DPP-4抑制剂时随机对照试验疗效与真实世界效果之间的差距

Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2017-08-11

本研究采用混合方法准实验设计,利用回顾性索赔数据比较2型糖尿病患者的真实世界HbA1c变化与随机对照试验报告结果。真实世界起始GLP-1受体激动剂(n=221)或DPP-4抑制剂(n=652)的患者HbA1c降低幅度小于随机对照试验报告值。药物依从性差约占真实世界与随机对照试验预期结果之间差距的四分之三。

要点

  • 真实世界起始GLP-1受体激动剂或DPP-4抑制剂的患者HbA1c降低幅度小于随机对照试验报告值。
  • 药物依从性差约占真实世界与随机对照试验预期结果之间差距的四分之三。
  • 基线HbA1c、额外用药和依从性是真实世界HbA1c变化的显著解释因素。

核心结论

  • 药物依从性差是真实世界效果显著低于随机对照试验疗效的主要原因,提示迫切需要有效解决2型糖尿病患者的依从性问题。

研究设计与样本

  • 混合方法准实验研究,使用回顾性索赔数据(Optum/Humedica)比较真实世界2型糖尿病患者起始GLP-1受体激动剂或DPP-4抑制剂12个月后HbA1c变化与已发表的随机对照试验结果。
  • 选取的真实世界患者与随机对照试验患者相似,并使用回归分析在真实世界数据中校正依从性差与依从性好的患者之间的差异,以解释随机对照试验与真实世界结果可能不同的原因。

主要发现

  • 真实世界起始GLP-1受体激动剂(n=221)或DPP-4抑制剂(n=652)的患者HbA1c降低幅度分别为-0.52%(-6 mmol/mol)和-0.51%(-6 mmol/mol),小于随机对照试验报告的-1.30%(-14 mmol/mol)(来自七项GLP-1受体激动剂随机对照试验,n=2,600)和-0.68%(-8 mmol/mol)(来自四项DPP-4抑制剂随机对照试验,n=1,889)。
  • 基线HbA1c、额外用药和依从性是真实世界HbA1c变化的显著解释因素。
  • 模型估计的随机对照试验疗效(GLP-1受体激动剂:-1.04% [-12 mmol/mol],DPP-4抑制剂:-0.69% [-8 mmol/mol])在随机对照试验报告范围之内(GLP-1受体激动剂:-0.84%至-1.60% [-9至-18 mmol/mol],DPP-4抑制剂:-0.47%至-0.90% [-5至-10 mmol/mol])。
  • 药物依从性差约占真实世界与随机对照试验预期结果之间差距的四分之三(差距=0.51% [6 mmol/mol] GLP-1受体激动剂;0.18% [3 mmol/mol] DPP-4抑制剂)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to estimate and explain the gap between clinical efficacy and real-world (RW) effectiveness of type 2 diabetes medications. RESEARCH DESIGN AND METHODS: This mixed-methods quasi-experimental study used retrospective claims (Optum/Humedica) to compare the change in HbA1c of RW patients with type 2 diabetes 12 months after starting a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase 4 (DPP-4) inhibitor with published findings from randomized controlled trials (RCTs) evaluating these drugs. Selected RW patients were similar to RCT patients, and regression analysis was used in the RW data to adjust for differences between poorly adherent and adherent patients to explain why RCT and RW findings may differ. RESULTS: RW patients initiating a GLP-1 RA (n = 221) or a DPP-4 (n = 652) experienced smaller reductions in HbA1c (GLP-1 RA: -0.52% [-6 mmol/mol], DPP-4: -0.51% [-6 mmol/mol])than reported in RCTs (-1.30% [-14 mmol/mol] from seven GLP-1 RA RCTs, n = 2,600; -0.68% [-8 mmol/mol] from four DPP-4 RCTs, n = 1,889). Baseline HbA1c, additional medications, and adherence were significant explanatory factors in the RW HbA1c change. Modeled estimates of RCT efficacy (-1.04% GLP-1 RA [-12 mmol/mol], -0.69% DPP-4 [-8 mmol/mol]) were within the RCTs' reported range (GLP-1 RA: -0.84% to -1.60% [-9 to -18 mmol/mol], DPP-4: -0.47% to -0.90% [-5 to -10 mmol/mol]). Poor medication adherence accounted for approximately three-fourths of the gap between RW and expected RCT results (gap = 0.51% [6 mmol/mol] GLP-1 RA; 0.18% [3 mmol/mol] DPP-4). CONCLUSIONS: Poor medication adherence is primarily why RW effectiveness is significantly less than RCT efficacy, suggesting an urgent need to effectively address adherence among patients with type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Carls GS, Tuttle E, Tan RD, et al. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. Diabetes Care. 2017. PMID: 28801475. doi:10.2337/dc16-2725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。